Prevents postmenopausal osteoporosis. ANDA 206887, held by Macleods Pharmaceuticals. Ibandronate Sodium.
As of Nov 21, 2026, ANDA 206887 (Ibandronate Sodium), held by Macleods Pharmaceuticals, was first approved by FDA on Oct 31, 2017, with 3 approved supplements and 0 published complete response letters.
Ibandronate sodium is a bisphosphonate indicated for the treatment and prevention of postmenopausal osteoporosis.. Limitations of Use The optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. 1.1 Treatment and Prevention of Postmenopausal Osteoporosis Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. Ibandronate sodium tablets increases bone mineral density (BMD) and reduce the incidence of vertebral fractures. 1.2 Important Limitations of Use The optimal duration of use has not been determined.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ibandronate SodiumEQ 150MG BASE · tablet;oral | Ibandronate Sodium | Rx |
| Feb 3, 2026 | Supplement 27Labeling · Standard review | Approved | None posted |
| Oct 8, 2024 | Supplement 25Manufacturing | Approved | None posted |
| Jun 7, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Oct 31, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters